View Item 

Show simple item record

Efficacy and Tolerability of the New Antiepileptic Drugs, II: Treatment of Refractory Epilepsy: Report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society

dc.contributor.authorFrench, Jacqueline A.en_US
dc.contributor.authorKanner, Andres M.en_US
dc.contributor.authorBautista, Jocelynen_US
dc.contributor.authorAbou-Khalil, Bassel W.en_US
dc.contributor.authorBrowne, Thomasen_US
dc.contributor.authorHarden, Cynthia L.en_US
dc.contributor.authorTheodore, William H.en_US
dc.contributor.authorBazil, Carlen_US
dc.contributor.authorStern, Johnen_US
dc.contributor.authorSchachter, Steven C.en_US
dc.contributor.authorBergen, Donnaen_US
dc.contributor.authorHirtz, Deborahen_US
dc.contributor.authorMontouris, Georgia D.en_US
dc.contributor.authorNespeca, Marken_US
dc.contributor.authorGidal, Barryen_US
dc.contributor.authorMarks, William J.en_US
dc.contributor.authorTurk, William R.en_US
dc.contributor.authorFischer, James H.en_US
dc.contributor.authorBourgeois, Blaiseen_US
dc.contributor.authorWilner, Andrewen_US
dc.contributor.authorFaught, R. Edwarden_US
dc.contributor.authorSachdeo, Rajesh C.en_US
dc.contributor.authorBeydoun, Ahmad A.en_US
dc.contributor.authorGlauser, Tracy A.en_US
dc.date.accessioned2010-04-01T14:43:31Z
dc.date.available2010-04-01T14:43:31Z
dc.date.issued2004-05en_US
dc.identifier.citationFrench, Jacqueline A.; Kanner, Andres M.; Bautista, Jocelyn; Abou-Khalil, Bassel; Browne, Thomas; Harden, Cynthia L.; Theodore, William H.; Bazil, Carl; Stern, John; Schachter, Steven C.; Bergen, Donna; Hirtz, Deborah; Montouris, Georgia D.; Nespeca, Mark; Gidal, Barry; Marks, William J.; Turk, William R.; Fischer, James H.; Bourgeois, Blaise; Wilner, Andrew; Faught, R. Edward; Sachdeo, Rajesh C.; Beydoun, Ahmad; Glauser, Tracy A. (2004). "Efficacy and Tolerability of the New Antiepileptic Drugs, II: Treatment of Refractory Epilepsy: Report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society." Epilepsia 45(5): 410-423. <http://hdl.handle.net/2027.42/65170>en_US
dc.identifier.issn0013-9580en_US
dc.identifier.issn1528-1167en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/65170
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=15101822&dopt=citationen_US
dc.description.abstractPurpose: To assess the evidence demonstrating efficacy, tolerability, and safety of seven new antiepileptic drugs (AEDs) [gabapentin (GBP), lamotrigine (LTG), topiramate (TPM), tiagabine (TGB), oxcarbazepine (OXC), levetiracetam (LEV), and zonisamide (ZNS)] in the treatment of children and adults with refractory partial and generalized epilepsies. Methods: A 23-member committee, including general neurologists, pediatric neurologists, epileptologists, and doctors in pharmacy, evaluated the available evidence based on a structured literature review including MEDLINE, Current Contents , and Cochrane Library for relevant articles from 1987 to March 2003. Results: All of the new AEDs were found to be appropriate for adjunctive treatment of refractory partial seizures in adults. GBP can be effective for the treatment of mixed seizure disorders, and GBP, LTG, OXC, and TPM for the treatment of refractory partial seizures in children. Limited evidence suggests that LTG and TPM also are effective for adjunctive treatment of idiopathic generalized epilepsy in adults and children, as well as treatment of the Lennox–Gastaut syndrome. Conclusions: The choice of AED depends on seizure and/or syndrome type, patient age, concomitant medications, and AED tolerability, safety, and efficacy. The results of this evidence-based assessment provide guidelines for the prescription of AEDs for patients with refractory epilepsy and identify those seizure types and syndromes for which more evidence is necessary.en_US
dc.format.extent125368 bytes
dc.format.extent3110 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Science Incen_US
dc.rights2004 International League Against Epilepsyen_US
dc.titleEfficacy and Tolerability of the New Antiepileptic Drugs, II: Treatment of Refractory Epilepsy: Report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Societyen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelMedicine (General)en_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationum**** Department of Neurology, University of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationother* University of Pennsylvania, Philadelphia, Pennsylvaniaen_US
dc.contributor.affiliationother† Department of Neurological Sciences, Rush Medical College, Chicago, Illinoisen_US
dc.contributor.affiliationother†† The Cleveland Clinic Foundation, Cleveland, Ohioen_US
dc.contributor.affiliationother§ Vanderbilt University Medical Center, Nashville, Tennesseeen_US
dc.contributor.affiliationotherBoston University Medical Center, Boston, Massachusettsen_US
dc.contributor.affiliationother¶ Weill Medical College of Cornell University, New York, New Yorken_US
dc.contributor.affiliationother** National Institutes of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Marylanden_US
dc.contributor.affiliationother†† Columbia Presbyterian Medical Center, New York, New Yorken_US
dc.contributor.affiliationother†† Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusettsen_US
dc.contributor.affiliationother§§ Children's Hospital, San Diego, Californiaen_US
dc.contributor.affiliationotherSchool of Pharmacy and Department of Neurology, University of Wisconsin Hospital and Clinics, Madison, Wisconsinen_US
dc.contributor.affiliationother¶¶ University of California San Francisco Epilepsy Center, San Francisco, Californiaen_US
dc.contributor.affiliationother*** Nemours Children's Clinic, Division of Neurology, Jacksonville, Floridaen_US
dc.contributor.affiliationother††† University of Illinois College of Pharmacy, Department of Pharmacy Practice and Neurology, Colleges of Pharmacy and Medicine, Chicago, Illinoisen_US
dc.contributor.affiliationother††† Department of Neurology, Children's Hospital, Boston, Massachusettsen_US
dc.contributor.affiliationother§§§ Providence, Rhode Islanden_US
dc.contributor.affiliationotherDepartment of Neurology, University of Alabama School of Medicine, Birmingham, Alabamaen_US
dc.contributor.affiliationother¶¶¶ Department of Neurology, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jerseyen_US
dc.contributor.affiliationother†††† Department of Neurology, Children's Hospital Medical Center, Cincinnati, Ohio, U.S.A.en_US
dc.identifier.pmid15101822en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/65170/1/j.0013-9580.2004.06304.x.pdf
dc.identifier.doi10.1111/j.0013-9580.2004.06304.xen_US
dc.identifier.sourceEpilepsiaen_US
dc.identifier.citedreferenceHauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia 1993 ; 34 : 453 – 68.en_US
dc.identifier.citedreferenceHauser WA, Annegers JF, Kurland LT. Prevalence of epilepsy in Rochester, Minnesota: 1940-1980. Epilepsia 1991 ; 32 : 429 – 45.en_US
dc.identifier.citedreferenceFrench J, Smith M, Faught E, et al. Practice advisory: the use of felbamate in the treatment of patients with intractable epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 1999 ; 40 : 803 – 8 and Neurology 1999 ; 52 : 1540 – 5.en_US
dc.identifier.citedreferenceAnhut H, Ashman P, Feuerstein TJ, et al. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study: the International Gabapentin Study Group. Epilepsia 1994 ; 35 : 795 – 801.en_US
dc.identifier.citedreference5.  UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet 1990 ; 335 : 1114 – 7.en_US
dc.identifier.citedreferenceThe US Gabapentin Study Group No. 5. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. Neurology 1993 ; 43 : 2292 – 8.en_US
dc.identifier.citedreferenceSivenius J, Kalviainen R, Ylinen A, et al. Double-blind study of Gabapentin in the treatment of partial seizures. Epilepsia 1991 ; 32 : 539 – 42.en_US
dc.identifier.citedreferenceFisher RS, Sachdeo RC, Pellock J, et al. Rapid initiation of gabapentin: a randomized, controlled trial. Neurology 2001 ; 56 : 743 – 8.en_US
dc.identifier.citedreferenceAsconape J, Diedrich A, DellaBadia J. Myoclonus associated with the use of gabapentin. Epilepsia 2000 ; 41 : 479 – 81.en_US
dc.identifier.citedreferenceBuetefisch CM, Gutierrez A, Gutmann L. Choreoathetotic movements: a possible side effect of gabapentin. Neurology 1996 ; 46 : 851 – 2.en_US
dc.identifier.citedreferenceReeves AL, So EL, Sharbrough FW, et al. Movement disorders associated with the use of gabapentin. Epilepsia 1996 ; 37 : 988 – 90.en_US
dc.identifier.citedreferenceNorton JW, Quarles E. Gabapentin-related dyskinesia. J Clin Psychopharmacol 2001 ; 21 : 623 – 4.en_US
dc.identifier.citedreferenceGil-Nagel A, Gapany S, Blesi K, et al. Incontinence during treatment with gabapentin. Neurology 1997 ; 48 : 1467 – 8.en_US
dc.identifier.citedreferenceMatsuo F, Bergen D, Faught E, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures: U.S. Lamotrigine Protocol 0.5 Clinical Trial Group. Neurology 1993 ; 43 : 2284 – 91.en_US
dc.identifier.citedreferenceMessenheimer J, Ramsay RE, Willmore LJ, et al. Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial. Epilepsia 1994 ; 35 : 113 – 21.en_US
dc.identifier.citedreferenceSchapel GJ, Beran RG, Vajda FJ, et al. Double-blind, placebo controlled, crossover study of lamotrigine in treatment of resistant partial seizures. J Neurol Neurosurg Psychiatry 1993 ; 56 : 448 – 53.en_US
dc.identifier.citedreference17.  Korean Topiramate Study Group. Topiramate in medically intractable partial epilepsies: double-blind placebo-controlled randomized parallel group trial. Epilepsia 1999 ; 40 : 1767 – 74.en_US
dc.identifier.citedreferenceBen-Menachem E, Henrisksen O, Dam M, et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996 ; 37 : 539 – 43.en_US
dc.identifier.citedreferenceFaught E, Wilder BJ, Ramsay RE, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages: Topiramate YD Study Group. Neurology 1996 ; 46 : 1684 – 90.en_US
dc.identifier.citedreferencePrivitera M, Fincham R, Penry J, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000 mg daily dosages: Topiramate YE Study Group. Neurology 1996 ; 46 : 1678 – 83.en_US
dc.identifier.citedreferenceSharief M, Viteri C, Ben-Menachem E, et al. Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Res 1996 ; 25 : 217 – 24.en_US
dc.identifier.citedreferenceTassinari CA, Michelucci R, Chauvel P, et al. Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia 1996 ; 37 : 763 – 8.en_US
dc.identifier.citedreferenceYen DJ, Yu HY, Guo YC, et al. A double-blind, placebo-controlled study of topiramate in adult patients with refractory partial epilepsy. Epilepsia 2000 ; 41 : 1162 – 6.en_US
dc.identifier.citedreferenceWang Y, Zhou D, Pauli E, et al. Topiramate on ictal seizure semiology: a quantitative, randomized, low and medium dose-controlled study. Epilepsy Res 2001 ; 46 : 271 – 7.en_US
dc.identifier.citedreferenceBiton V, Edwards KR, Montouris GD, et al. Ann Pharmacother 2001 ; 35 : 173 – 9.en_US
dc.identifier.citedreferenceSachdeo RC, Leroy RF, Krauss GL, et al. Tiagabine therapy for complex partial seizures: a dose-frequency study: the Tiagabine Study Group. Arch Neurol 1997 ; 54 : 595 – 601.en_US
dc.identifier.citedreferenceUthman BM, Rowan AJ, Ahmann PA, et al. Tiagabine for complex partial seizures: a randomized, add-on, dose-response trial. Arch Neurol 1998 ; 55 : 56 – 62.en_US
dc.identifier.citedreferenceRichens A, Chadwick DW, Duncan JS, et al. Adjunctive treatment of partial seizures with tiagabine: a placebo-controlled trial. Epilepsy Res 1995 ; 21 : 37 – 42.en_US
dc.identifier.citedreferenceDodrill CB, Arnett JL, Sommerville KW, Shu V. Cognitive and quality of life effects of differing dosages of tiagabine in epilepsy. Neurology 1997 ; 48 : 1025 – 31.en_US
dc.identifier.citedreferenceBarcs G, Walker EG, Elger CE, et al. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia 2000 ; 41 : 1597 – 607.en_US
dc.identifier.citedreferenceSchmidt D, Jacob R, Loiseau P, et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res 1993 ; 15 : 67 – 73.en_US
dc.identifier.citedreferenceFaught E, Ayala R, Montouris GG, et al. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 2001 ; 57 : 1774 – 9.en_US
dc.identifier.citedreferenceCereghino JJ, Biton V, Abou-Khalil B, et al. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000 ; 55 : 236 – 42.en_US
dc.identifier.citedreferenceShorvon SD, Lowenthal A, Janz D, et al. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures: European Levetiracetam Study Group. Epilepsia 2000 ; 41 : 1179 – 86.en_US
dc.identifier.citedreferenceBen-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia 2000 ; 41 : 1276 – 83.en_US
dc.identifier.citedreferenceCramer JA, Arrigo C, Van Hammee, et al. Effect of levetiracetam on epilepsy-related quality of life. N132 Study Group. Epilepsia 2000 ; 41 : 868 – 74.en_US
dc.identifier.citedreferenceBetts T, Waegemans T, Crawford P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure 2000 ; 9 : 80 – 7.en_US
dc.identifier.citedreferenceBergey GK, Morris HH, Rosenfeld W, et al. Gabapentin monotherapy: l. an 8-day, double-blind, dose-controlled, multicenter study in hospitalized patients with refractory complex partial or secondarily generalized seizures: the US Gabapentin Study Group 88/89. Neurology 1997 ; 49 : 739 – 45.en_US
dc.identifier.citedreferenceBeydoun A, Fischer J, Labar DR, et al. Gabapentin monotherapy, II: a 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures: the US Gabapentin Study Group 82.83. Neurology 1997 ; 49 : 746 – 52.en_US
dc.identifier.citedreferenceGilliam F, Vazquez B, Sackellares JC, et al. An active-control trial of lamotrigine monotherapy for partial seizures. Neurology 1998 ; 51 : 1018 – 25.en_US
dc.identifier.citedreferenceSachdeo RC, Reife RA, Lim P, et al. Topiramate monotherapy for partial onset seizures. Epilepsia 1997 ; 38 : 294 – 300.en_US
dc.identifier.citedreferenceSchachter SC, Vazquez B, Fisher RS, et al. Oxcarbazepine: double-blind, randomized, placebo-control, monotherapy trial for partial seizures. Neurology 1999 ; 52 : 732 – 7.en_US
dc.identifier.citedreferenceBeydoun A, Sachdeo RC, Rosenfeld WE, et al. Oxcarbazepine monotherapy for partial-onset seizures: a multicenter, double-blind, clinical trial. Neurology 2000 ; 54 : 2245 – 51.en_US
dc.identifier.citedreferenceSachdeo R, Beydoun A, Schachter S, et al. Oxcarbazepine (Trileptal) as monotherapy in patients with partial seizures. Neurology 2001 ; 57 : 864 – 71.en_US
dc.identifier.citedreferenceChadwick D, Leiderman DB, Sauermann W, et al. Gabapentin in generalized seizures. Epilepsy Res 1996 ; 25 : 191 – 7.en_US
dc.identifier.citedreferenceBhaumik S, Branford D, Duggirala C, et al. A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities. Seizure 1997 ; 6 : 127 – 33.en_US
dc.identifier.citedreferenceCrawford P, Ghadiali E, Lane R, et al. Gabapentin as an antiepileptic drug in man. J Neurol Neurosurg Psychiatry 1987 ; 50 : 682 – 6.en_US
dc.identifier.citedreferenceLangan Y, Duncan JS, Sander JW. An audit of the perceived efficacy and tolerability of gabapentin therapy in an out-patient cohort with chronic epilepsy. Eur Neurol 1999 ; 41 : 111 – 3.en_US
dc.identifier.citedreferenceThisj RD, Kerr MP. The outcome of prescribing novel anticonvulsants in an outpatient setting: factors affecting response to medication. Seizure 1998 ; 7 : 379 – 83.en_US
dc.identifier.citedreferenceWong IC, Chadwick DW, Fenwick PB, et al. The long-term use of gabapentin, lamotrigine, and vigabatrin in patients with chronic epilepsy. Epilepsia 1999 ; 40 : 1439 – 45.en_US
dc.identifier.citedreferenceBeran RG, Berkovic SF, Dunagan FM, et al. Double-blind, placebo-controlled, crossover study of lamotrigine in treatment-resistant generalised epilepsy. Epilepsia 1998 ; 39 : 1329 – 33.en_US
dc.identifier.citedreferenceBoas J, Dam M, Friis ML, et al. Controlled trial of lamotrigine (Lamictal) for treatment-resistant partial seizures. Acta Neurol Scand 1996 ; 94 : 247 – 52.en_US
dc.identifier.citedreferenceMarciani MG, Spanedda F, Bassetti MA, et al. Effect of lamotrigine on EEG paroxysmal abnormalities and background activity: a computerized analysis. Br J Clin Pharmacol 1996 ; 42 : 621 – 7.en_US
dc.identifier.citedreferenceSander JW, Patsalos PN, Oxley JR, et al. A randomised double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy. Epilepsy Res 1990 ; 6 : 221 – 6.en_US
dc.identifier.citedreferenceTrenite DG, Rentmeester TW, Scholtes FB, et al. Post-marketing surveillance of lamotrigine in The Netherlands: doctors' and patients' viewpoints. Pharm World Sci 2001 ; 23 : 1 – 5.en_US
dc.identifier.citedreferenceHoutkooper MA, Lammertsma A, Meyer JW, et al. Oxcarbazepine (GP 47.680): a possible alternative to carbamazepine ? Epilepsia 1987 ; 28 : 693 – 8.en_US
dc.identifier.citedreferenceBiton V, Montouris GD, Ritter F, et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures: Topiramate YTC Study Group. Neurology 1999 ; 52 : 1330 – 7.en_US
dc.identifier.citedreferenceCrawford P. An audit of topiramate use in a general neurology clinic. Seizure 1998 ; 7 : 207 – 11.en_US
dc.identifier.citedreferenceDooley JM, Camfield PR, Smith E, et al. Topiramate in intractable childhood onset epilepsy: a cautionary note. Can J Neurol Sci 1999 ; 26 : 271 – 3.en_US
dc.identifier.citedreferenceTatum WO, French JA, Faught E, et al. Postmarketing experience with topiramate and cognition. Epilepsia 2001 ; 42 : 1134 – 40.en_US
dc.identifier.citedreferenceAbou-Khalil B. Topiramate in the long-term management of refractory epilepsy: Topiramate YOL Study Group. Epilepsia 2000 ; 41 : S72 – 6.en_US
dc.identifier.citedreferenceLhatoo SD, Wong IC, Sander JW. Prognostic factors affecting long-term retention of topiramate in patients with chronic epilepsy. Epilepsia 2000 ; 41 : 338 – 41.en_US
dc.identifier.citedreferenceTartara A, Sartori I, Manni R, et al. Efficacy and safety of topiramate in refractory epilepsy: a long-term prospective trial. Ital J Neurol Sci 1996 ; 17 : 429 – 32.en_US
dc.identifier.citedreferenceBaker GA, Currie NG, Light MJ, et al. The effects of adjunctive topiramate therapy on seizure severity and health-related quality of life in patients with refractory epilepsy: a Canadian study. Seizure 2002 ; 11 : 6 – 15.en_US
dc.identifier.citedreferenceSingh BK, White-Scott S. Role of topiramate in adults with intractable epilepsy, mental retardation, and developmental disabilities. Seizure 2002 ; 11 : 47 – 50.en_US
dc.identifier.citedreferenceKelly K, Stephen LJ, Sills GJ, Brodie MJ. Topiramate in patients with learning disability and refractory epilepsy. Epilepsia 2002 ; 43 : 399 – 402.en_US
dc.identifier.citedreferenceKellett MW, Smith DF, Stockton PA, Chadwick DW. Topiramate in clinical practice: first year's postlicensing experience in a specialist epilepsy clinic. J Neurol Neurosurg Psychiatry 1999 ; 66 : 759 – 63.en_US
dc.identifier.citedreferenceAppleton R, Fichtner K, LaMoreaux L, et al. Gabapentin as add-on therapy in children with refractory partial seizures: a 12-week, multicentre, double-blind, placebo-controlled study: Gabapentin Paediatric Study Group. Epilepsia 1999 ; 40 : 1147 – 54.en_US
dc.identifier.citedreferenceDuchowny M, Pellock JM, Graf WD, et al. A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children: Lamictal Pediatric Partial Seizure Study Group. Neurology 1999 ; 53 : 1724 – 31.en_US
dc.identifier.citedreferenceElterman RD, Glauser TA, Wyllie E, et al. A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children: Topiramate YP Study Group. Neurology 1999 ; 52 : 1338 – 44.en_US
dc.identifier.citedreferenceArcas J, Ferrer T, Roche MC, et al. Hypohidrosis related to the administration of topiramate to children. Epilepsia 2001 ; 42 : 1363 – 5.en_US
dc.identifier.citedreferenceGlauser TA, Nigro M, Sachedo R, et al. Adjunctive therapy with oxcarbazepine in children with partial seizures: the Oxcarbazepine Pediatric Study Group. Neurology 2000 ; 54 : 2237 – 44.en_US
dc.identifier.citedreferenceGlauser TA, Pellock JM, Bebin M, et al. Efficacy and safety of levetiracetam in children with partial seizures: an open trial. Epilepsia 2002 ; 43 : 518 – 24.en_US
dc.identifier.citedreferenceShimizu T, Yamashita Y, Satoi M, et al. Heat stroke–like episode in a child caused by zonisamide. Brain Dev 1997 ; 19 : 366 – 8.en_US
dc.identifier.citedreferenceSheridan PH, Jacobs MP. The development of antiepileptic drugs for children: report from the NIH workshop, Bethesda, Md, Feb. 17-18, 1994. Epilepsy Res 1996 ; 23 : 87 – 92.en_US
dc.identifier.citedreferenceVossler DG. Exacerbation of seizures in Lennox-Gastaut syndrome by gabapentin. Neurology 1996 ; 46 : 852 – 3.en_US
dc.identifier.citedreferenceMotte J, Trevathan E, Arvidsson JF, et al. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome: Lamictal Lennox-Gastaut Study Group. N Engl J Med 1997 ; 337 : 1807 – 12.en_US
dc.identifier.citedreferenceEriksson AS, Nergardh A, Hoppu K. The efficacy of lamotrigine in children and adolescents with refractory generalized epilepsy: a randomized, double-blind, crossover study. Epilepsia 1998 ; 39 : 495 – 501.en_US
dc.identifier.citedreferenceDonaldson JA, Glauser TA, Olberding LS. Lamotrigine adjunctive therapy in childhood epileptic encephalopathy (the Lennox–Gastaut syndrome ). Epilepsia 1997 ; 38 : 68 – 73.en_US
dc.identifier.citedreferenceJanszky J, Rasonyi G, Halasz P, et al. Disabling erratic myoclonus during lamotrigine therapy with high serum level: report of two cases. Clin Neuropharmacol 2000 ; 23 : 86 – 9.en_US
dc.identifier.citedreferenceSachdeo RC, Glauser TA, Ritter F, et al. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome: Topiramate YL Study Group. Neurology 1999 ; 52 : 1882 – 7.en_US
dc.identifier.citedreferenceGlauser TA, Levisohn PM, Ritter F, et al. Topiramate in Lennox-Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial: Topiramate YL Study Group. Epilepsia 2000 ; 41 : S86 – 90.en_US
dc.identifier.citedreferenceMarson AG, Kadir ZA, Chadwick DW. New antiepileptic drugs: a systematic review of their efficacy and tolerability. BMJ 1996 ; 313 : 1169 – 74.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.0013-9580.2004.06304.x.pdf
Size:
122.4KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.